Suppr超能文献

半衰期在临床决策中的应用:缓释托吡酯(USL255)与速释托吡酯的药代动力学比较。

The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate.

作者信息

Gidal Barry E, Clark Annie M, Anders Bob, Gilliam Frank

机构信息

University of Wisconsin School of Pharmacy & Department of Neurology, Madison, WI 53705, United States.

Upsher-Smith Laboratories, Inc. 6701 Evenstad Drive, Maple Grove, MN 55369, United States.

出版信息

Epilepsy Res. 2017 Jan;129:26-32. doi: 10.1016/j.eplepsyres.2016.10.020. Epub 2016 Nov 9.

Abstract

OBJECTIVE

For extended-release drugs with multi-compartment kinetics, such as topiramate, effective half-life (t) may be a more clinically relevant parameter than elimination half-life (t). Using topiramate as a real-life example, the objective was to compare these half-life values for immediate- and extended-release topiramate (TPM-IR and USL255, respectively) to understand how drug pharmacokinetics may impact drug dosing recommendations.

METHODS

The t and t for USL255 and TPM-IR were compared using data from a phase I study (N=36) of 200mg USL255 administered once daily (QD) or TPM-IR twice daily (BID); effect of sampling duration on t was investigated. To further explore the relationship between half-life and dosing, steady-state PK was simulated for USL255 and TPM-IR.

RESULTS

As previously reported, mean t was similar between USL255 (80.2h) and TPM-IR (82.8h); TPM-IR t was ∼4 times longer than reported in the Topamax label (21h). In contrast, USL255 displayed a 1.5 fold longer t (55.7 vs 37.1h for TPM-IR). When t was calculated from 48 to 336h, values ranged from 28.8 to 82.8h. Simulated steady-state PK profiles of USL255 QD exhibited reduced plasma fluctuations during a dosing interval vs TPM-IR QD or BID.

SIGNIFICANCE

As expected for the same moiety, t of USL255 and TPM-IR were similar; however, the longer t for USL255 better approximates differences in recommend dosing (QD USL255 vs BID TPM-IR). Further, sampling duration impacted t, diminishing its predictive value for determining dose regimens; sampling-time differences may also explain t discrepancy between TPM-IR here versus Topamax label. As expected, steady-state simulations confirm that although TPM-IR has a long t, taking TPM-IR QD would lead to large plasma fluctuations. These data demonstrate that t may be less clinically meaningful than t and using t for some drugs may lead to erroneous conclusions regarding dosing regimens.

摘要

目的

对于具有多房室动力学的缓释药物,如托吡酯,有效半衰期(t)可能比消除半衰期(t)更具临床相关性。以托吡酯为例,目的是比较速释和缓释托吡酯(分别为TPM - IR和USL255)的这些半衰期值,以了解药物药代动力学如何影响给药建议。

方法

使用一项I期研究(N = 36)的数据比较USL255和TPM - IR的t和t,该研究中200mg USL255每日一次(QD)给药或TPM - IR每日两次(BID)给药;研究采样持续时间对t的影响。为进一步探讨半衰期与给药之间的关系,模拟了USL255和TPM - IR的稳态药代动力学。

结果

如先前报道,USL255(80.2小时)和TPM - IR(82.8小时)之间的平均t相似;TPM - IR的t比托吡酯标签中报道的(21小时)长约4倍。相比之下,USL255的t长1.5倍(TPM - IR为55.7小时对37.1小时)。当从48小时至336小时计算t时,值范围为28.8至82.8小时。与TPM - IR QD或BID相比,USL255 QD的模拟稳态药代动力学曲线在给药间隔期间血浆波动减小。

意义

对于相同部分,正如预期的那样,USL255和TPM - IR的t相似;然而,USL255较长的t更好地近似了推荐给药的差异(USL255 QD对TPM - IR BID)。此外,采样持续时间影响t,降低了其在确定给药方案方面的预测价值;采样时间差异也可能解释此处TPM - IR与托吡酯标签之间t的差异。正如预期的那样,稳态模拟证实,尽管TPM - IR的t很长,但每日一次服用TPM - IR会导致较大的血浆波动。这些数据表明,t可能比t在临床上意义较小,并且对某些药物使用t可能会导致关于给药方案的错误结论。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验